Format

Send to

Choose Destination
G Ital Dermatol Venereol. 2017 Feb;152(1):13-17. doi: 10.23736/S0392-0488.16.05201-9. Epub 2016 Feb 18.

Efficacy and safety of a 12-month treatment with a combination of hydroxypinacolone retinoate and retinol glycospheres as maintenance therapy in acne patients after oral isotretinoin.

Author information

1
Section of Dermatology, Department of Medical Sciences, University of Ferrara, Sant'Anna Hospital, Ferrara, Italy - vincenzo.bettoli@gmail.com.
2
Section of Dermatology, Department of Medical Sciences, University of Ferrara, Sant'Anna Hospital, Ferrara, Italy.

Abstract

BACKGROUND:

A correct therapeutic management of acne should include a maintenance therapy to prevent recurrences after discontinuing a successful treatment. The aim of this study is to investigate efficacy and safety of a 12-month maintenance treatment with a product, based on Retinsphere technology that combines retinol encapsulated in glycospheres and hydroxypinacolone retinoate (Biretix gelĀ®), to control acne relapse after a treatment with oral isotretinoin (O.I.).

METHODS:

The study consisted of 2 phases: active treatment phase (AP) and maintenance phase (MP). In the AP, 40 consecutive patients with moderate facial acne were treated with O.I. until acne remission. Then, the patients entered in the MP and were treated with Biretix gelĀ® once-daily for 12 months. The efficacy parameter was the relapse rate during MP.

RESULTS:

Thirty-nine patients completed the study. Relapse appeared in 6 patients (15.38%). The new product with Retinsphere technology was well tolerated and none of the subjects complained of adverse events.

CONCLUSIONS:

Our findings seems to provide favorable evidence of the efficacy and the safety of this new product in the maintenance treatment after O.I. in patient with moderate acne. The efficacy is maintain for a period as long as a year after O.I. suspension.

PMID:
26889724
DOI:
10.23736/S0392-0488.16.05201-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center